These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37070445)

  • 1. Current Medicinal Insights on Synthetic Small Molecules and Natural Origin Products as PD-1/PD-L1 Inhibitors.
    Pandey S; Kurmi BD; Patel P
    Curr Top Med Chem; 2023; 23(18):1765-1781. PubMed ID: 37070445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
    Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
    Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.
    Wu Q; Jiang L; Li SC; He QJ; Yang B; Cao J
    Acta Pharmacol Sin; 2021 Jan; 42(1):1-9. PubMed ID: 32152439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
    Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
    Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
    Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
    ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
    Lin X; Lu X; Luo G; Xiang H
    Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.
    Awadasseid A; Wu Y; Zhang W
    Life Sci; 2021 Oct; 282():119813. PubMed ID: 34256042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets.
    Awadasseid A; Wang R; Sun S; Zhang F; Wu Y; Zhang W
    Biomed Pharmacother; 2024 Mar; 172():116257. PubMed ID: 38350367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
    Ai L; Chen J; Yan H; He Q; Luo P; Xu Z; Yang X
    Drug Des Devel Ther; 2020; 14():3625-3649. PubMed ID: 32982171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
    Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).
    Baglini E; Salerno S; Barresi E; Marzo T; Settimo FD; Taliani S
    Mini Rev Med Chem; 2022; 22(14):1816-1827. PubMed ID: 35176979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer.
    Islam MK; Stanslas J
    Pharmacol Ther; 2021 Nov; 227():107870. PubMed ID: 33895183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
    Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
    Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
    Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
    Molecules; 2019 May; 24(11):. PubMed ID: 31151293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
    Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
    Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated patent review on PD-1/PD-L1 antagonists (2022-present).
    Uzar W; Kaminska B; Rybka H; Skalniak L; Magiera-Mularz K; Kitel R
    Expert Opin Ther Pat; 2024 Aug; 34(8):627-650. PubMed ID: 38903044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.